Menu
Search
|

Menu

Close
X

EyeGate Pharmaceuticals Inc EYEG.OQ (NASDAQ Stock Exchange Capital Market)

0.48 USD
+0.00 (+1.03%)
As of Nov 16
chart
Previous Close 0.47
Open 0.47
Volume 177,162
3m Avg Volume 240,914
Today’s High 0.49
Today’s Low 0.42
52 Week High 1.38
52 Week Low 0.28
Shares Outstanding (mil) 43.44
Market Capitalization (mil) 18.24
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
0
FY16
1
FY15
0
EPS (USD)
FY18
-0.212
FY17
-0.960
FY16
-1.508
FY15
-4.009
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
12.91
20.58
Price to Book (MRQ)
vs sector
1.31
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
0.07
13.84
LT Debt to Equity (MRQ)
vs sector
0.01
9.93
Return on Investment (TTM)
vs sector
-109.00
13.58
Return on Equity (TTM)
vs sector
-133.92
15.11

EXECUTIVE LEADERSHIP

Paul Chaney
Chairman of the Board, Since
Salary: --
Bonus: --
Stephen From
President, Director, Since 2017
Salary: $400,000.00
Bonus: $275,000.00
Sarah Romano
Chief Financial Officer, Corporate Controller, Since 2018
Salary: --
Bonus: --
Lisa Brandano
Vice President - Clinical Operations, Since 2017
Salary: --
Bonus: --
Michael Manzo
Vice President - Engineering, Since
Salary: $250,000.00
Bonus: $105,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

271 Waverley Oaks Rd Ste 108
WALTHAM   MA   02452-8475

Phone: +1781.7889043

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

SPONSORED STORIES